PharmAgents: Building a Virtual Pharma with Large Language Model Agents

TL;DR

PharmAgents presents a virtual pharmaceutical ecosystem that employs an LLM-driven multi-agent framework to automate the entire small-molecule drug discovery pipeline—from target discovery to preclinical evaluation. The system decomposes the workflow into four modules (target discovery, lead identification, lead optimization, PCC evaluation) with specialized agents and domain tools that provide transparent, interpretable decision-making. Empirical results show high target-screening plausibility, substantial gains over state-of-the-art design methods, and robust toxicity and synthesizability analyses, underpinned by self-evolving capabilities through experiential learning. This approach promises faster, more transparent drug discovery and lays groundwork for extended drug lifecycle management using autonomous AI agents.

Abstract

The discovery of novel small molecule drugs remains a critical scientific challenge with far-reaching implications for treating diseases and advancing human health. Traditional drug development--especially for small molecule therapeutics--is a highly complex, resource-intensive, and time-consuming process that requires multidisciplinary collaboration. Recent breakthroughs in artificial intelligence (AI), particularly the rise of large language models (LLMs), present a transformative opportunity to streamline and accelerate this process. In this paper, we introduce PharmAgents, a virtual pharmaceutical ecosystem driven by LLM-based multi-agent collaboration. PharmAgents simulates the full drug discovery workflow--from target discovery to preclinical evaluation--by integrating explainable, LLM-driven agents equipped with specialized machine learning models and computational tools. Through structured knowledge exchange and automated optimization, PharmAgents identifies potential therapeutic targets, discovers promising lead compounds, enhances binding affinity and key molecular properties, and performs in silico analyses of toxicity and synthetic feasibility. Additionally, the system supports interpretability, agent interaction, and self-evolvement, enabling it to refine future drug designs based on prior experience. By showcasing the potential of LLM-powered multi-agent systems in drug discovery, this work establishes a new paradigm for autonomous, explainable, and scalable pharmaceutical research, with future extensions toward comprehensive drug lifecycle management.

Figures (15)

• Figure 1: The Virual Pharma (PharmAgents) simulates the drug discovery process from target discovery to preclinical evaluation.
• Figure 2: Overall workflow of the PharmAgents.
• Figure 3: Workflow and example outputs of Target Discovery module.
• Figure 4: Workflow and example outputs from Lead Identification module.
• Figure 5: Workflow and example outputs of Lead Optimization module.